TY - JOUR
T1 - Interleukin-1B gene promoter variants are associated with an increased risk of gastric cancer in a Chinese population
AU - Yang, Jie
AU - Hu, Zhibin
AU - Xu, Yaochu
AU - Shen, Jin
AU - Niu, Juyin
AU - Hu, Xu
AU - Guo, Jiantao
AU - Wei, Qingyi
AU - Wang, Xinru
AU - Shen, Hongbing
N1 - Funding Information:
Supported by National Key Basic Research and Development Program of China: 2002CB512900; National Natural Science Foundation of China, Grant number: 30271148 and 30170827.
PY - 2004/11/25
Y1 - 2004/11/25
N2 - Studies suggest that IL-1β (encoded by IL-1B gene) is a pro-inflammatory cytokine and potent inhibitor of gastric acid secretion, which is proposed as a key determinant in gastric carcinogenesis. Two potentially functional polymorphisms (C-31T and T-511C) in the IL-1B promoter were suggested to be correlated with alteration of Helicobacter pylori infection and IL-1β expression and therefore may be associated with risk of gastric cancer. To test the hypothesis that these two polymorphisms are associated with gastric cancer risk, we performed a case-control study of 280 histologically confirmed gastric cancer patients and 258 age, sex frequency-matched cancer-free controls in a Chinese population. Multivariate logistic regression analyses revealed that the risks (adjusted odds ratio [OR] and 95% confidence interval [CI]) associated with the IL-1B variant genotypes were 1.64 (95% CI, 1.01-2.66) for -31TT and 1.52 (95% CI, 0.91-2.54) for -511CC, respectively, compared with their wild-type homozygotes. The risks were significantly more evident in individuals with H. pylori infection (adjusted OR, 2.14; 95% CI, 1.13-4.06 for -31TT; adjusted OR, 2.00; 95% CI, 1.02-3.89 for -511CC), which was consistent with the biological effects of IL-1β. When we used the haplotype analyses and assumed the IL-1B -31T and -511C as risk alleles, no synergistic effect was found between these two loci. These findings indicate that these two IL-1B promoter variants may contribute to the risk of developing gastric cancer in the Chinese population, especially in individuals with H. pylori infection.
AB - Studies suggest that IL-1β (encoded by IL-1B gene) is a pro-inflammatory cytokine and potent inhibitor of gastric acid secretion, which is proposed as a key determinant in gastric carcinogenesis. Two potentially functional polymorphisms (C-31T and T-511C) in the IL-1B promoter were suggested to be correlated with alteration of Helicobacter pylori infection and IL-1β expression and therefore may be associated with risk of gastric cancer. To test the hypothesis that these two polymorphisms are associated with gastric cancer risk, we performed a case-control study of 280 histologically confirmed gastric cancer patients and 258 age, sex frequency-matched cancer-free controls in a Chinese population. Multivariate logistic regression analyses revealed that the risks (adjusted odds ratio [OR] and 95% confidence interval [CI]) associated with the IL-1B variant genotypes were 1.64 (95% CI, 1.01-2.66) for -31TT and 1.52 (95% CI, 0.91-2.54) for -511CC, respectively, compared with their wild-type homozygotes. The risks were significantly more evident in individuals with H. pylori infection (adjusted OR, 2.14; 95% CI, 1.13-4.06 for -31TT; adjusted OR, 2.00; 95% CI, 1.02-3.89 for -511CC), which was consistent with the biological effects of IL-1β. When we used the haplotype analyses and assumed the IL-1B -31T and -511C as risk alleles, no synergistic effect was found between these two loci. These findings indicate that these two IL-1B promoter variants may contribute to the risk of developing gastric cancer in the Chinese population, especially in individuals with H. pylori infection.
KW - Gastric cancer
KW - H. pylori infection
KW - IL-1B polymorphisms
KW - Molecular epidemiology
UR - http://www.scopus.com/inward/record.url?scp=5644262478&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=5644262478&partnerID=8YFLogxK
U2 - 10.1016/j.canlet.2004.07.012
DO - 10.1016/j.canlet.2004.07.012
M3 - Article
C2 - 15488638
AN - SCOPUS:5644262478
SN - 0304-3835
VL - 215
SP - 191
EP - 198
JO - Cancer Letters
JF - Cancer Letters
IS - 2
ER -